H3 K27M clinical trials at UCLA

1 research study open to eligible people

Showing trials for

  • ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)

    open to all eligible people

    This is a randomized, double-blind, placebo-controlled, parallel-group, international, Phase 3 study in patients with newly diagnosed H3 K27M-mutant diffuse glioma to assess whether treatment with ONC201 following frontline radiotherapy will extend overall survival and progression-free survival in this population. Eligible participants will have histologically diagnosed H3 K27M-mutant diffuse glioma and have completed standard frontline radiotherapy.

    Los Angeles, California and other locations

Our lead scientists for H3 K27M research studies include .

Last updated: